ZA200906989B - Therapeutic agent for glaucoma containing adenosine derivative as active ingredient - Google Patents

Therapeutic agent for glaucoma containing adenosine derivative as active ingredient

Info

Publication number
ZA200906989B
ZA200906989B ZA200906989A ZA200906989A ZA200906989B ZA 200906989 B ZA200906989 B ZA 200906989B ZA 200906989 A ZA200906989 A ZA 200906989A ZA 200906989 A ZA200906989 A ZA 200906989A ZA 200906989 B ZA200906989 B ZA 200906989B
Authority
ZA
South Africa
Prior art keywords
active ingredient
therapeutic agent
adenosine derivative
containing adenosine
glaucoma containing
Prior art date
Application number
ZA200906989A
Other languages
English (en)
Inventor
Atsushi Shimazaki
Noriko Kawabata
Tomoko Kirihara
Jayson M Rieger
Robert D Thompson
Original Assignee
Santen Pharmaceutical Co Ltd
Pgxhealth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Pgxhealth Llc filed Critical Santen Pharmaceutical Co Ltd
Publication of ZA200906989B publication Critical patent/ZA200906989B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200906989A 2007-04-16 2009-10-07 Therapeutic agent for glaucoma containing adenosine derivative as active ingredient ZA200906989B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007106915A JP2008266143A (ja) 2007-04-16 2007-04-16 アデノシン誘導体を有効成分として含有する緑内障治療剤

Publications (1)

Publication Number Publication Date
ZA200906989B true ZA200906989B (en) 2010-06-30

Family

ID=39875791

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906989A ZA200906989B (en) 2007-04-16 2009-10-07 Therapeutic agent for glaucoma containing adenosine derivative as active ingredient

Country Status (15)

Country Link
US (2) US20100093770A1 (fr)
EP (1) EP2134174A4 (fr)
JP (2) JP2008266143A (fr)
KR (1) KR20090128495A (fr)
CN (1) CN101677544A (fr)
AU (1) AU2008241496A1 (fr)
BR (1) BRPI0809953A2 (fr)
CA (1) CA2684866A1 (fr)
EA (1) EA015971B1 (fr)
IL (1) IL201418A0 (fr)
MX (1) MX2009011076A (fr)
NZ (1) NZ580165A (fr)
UA (1) UA100376C2 (fr)
WO (1) WO2008130520A1 (fr)
ZA (1) ZA200906989B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
EP2523669B1 (fr) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combinaison, nécessaire et méthode utilisés pour réduire la pression intraoculaire
AU2011230618A1 (en) * 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
JP2012180346A (ja) * 2011-02-10 2012-09-20 Santen Pharmaceut Co Ltd 親水性薬物の薬物移行性を改善した水性組成物
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
WO2017137528A1 (fr) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Agoniste du récepteur a1 de l'adénosine pour utilisation dans le traitement de l'état de mal épileptique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
BRPI0414277A (pt) * 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1778712B1 (fr) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a2a
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
WO2008133129A1 (fr) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif

Also Published As

Publication number Publication date
EP2134174A4 (fr) 2011-05-25
EA200901402A1 (ru) 2010-04-30
US20130109646A1 (en) 2013-05-02
JP2010524933A (ja) 2010-07-22
CN101677544A (zh) 2010-03-24
EP2134174A1 (fr) 2009-12-23
BRPI0809953A2 (pt) 2014-09-23
JP2008266143A (ja) 2008-11-06
KR20090128495A (ko) 2009-12-15
AU2008241496A1 (en) 2008-10-30
UA100376C2 (en) 2012-12-25
JP4923141B2 (ja) 2012-04-25
US20100093770A1 (en) 2010-04-15
NZ580165A (en) 2012-07-27
MX2009011076A (es) 2010-01-20
WO2008130520A1 (fr) 2008-10-30
IL201418A0 (en) 2010-06-16
EA015971B1 (ru) 2012-01-30
CA2684866A1 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
EP1864666A4 (fr) Agent protecteur pour la cellule neuronale retinienne contenant un derive de prostaglandine f2 alpha comme ingredient actif
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EP2030974A4 (fr) Composés non nucléosidiques hétérocycliques, leur préparation, compositions pharmaceutiques, et leur utilisation en tant qu'agents antiviraux
IL199554B (en) Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
EP2130552A4 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
ZA200908019B (en) Controlled release pharmaceutical compositions for prolonged effect
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
IL192150A0 (en) Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease
PL1932522T3 (pl) Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs
EP2196206A4 (fr) Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif
PL2154968T3 (pl) Kombinacje grzybobójczych substancji czynnych
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
ZA200800698B (en) Pyrazole derivatives as therapeutic agents
EP2583972A4 (fr) Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif
EP2098228A4 (fr) Agent anti-inflammatoire contenant du 2-aminophénol ou un dérivé de celui-ci en tant que principe actif
HK1118807A1 (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient
EP1884237A4 (fr) Agent protecteur de neurocyte comprenant un derive amidino en tant que substance active
EP1967201A4 (fr) Agent therapeutique pour la peau ou agent favorisant la regeneration de la peau contenant de la desacyl-ghreline ou un derive de celle-ci utilise en tant que principe actif
HK1139064A1 (en) Therapeutic agent for meniere's disease
ZA200901118B (en) Formulations for the controlled release of agrochemical active agents